Purpose of review Pharmacoepidemiologic studies employing large databases are critical to evaluating the effectiveness and safety of drug exposures in large and diverse populations. Because treatment is not randomized, researchers must select a relevant comparison group for the treatment of interest. The comparator group can consist of individuals initiating: (1) a similarly indicated treatment (active comparator), (2) a treatment used for a different indication (inactive comparator), or (3) no particular treatment (non-initiators). Herein, we review recent literature and describe considerations and implications of comparator selection in pharmacoepidemiologic studies. Recent findings Comparator selection depends on the scientific question and feasibility constraints. Because pharmacoepidemiologic studies rely on the choice to initiate or not initiate a specific treatment, rather than randomization, they are at-risk for confounding related to the comparator choice including by indication, disease severity, and frailty. We describe forms of confounding specific to pharmacoepidemiologic studies and discuss each comparator along with informative examples and a case study. We provide commentary on potential issues relevant to comparator selection in each study, highlighting the importance of understanding the population in whom the treatment is given and how patient characteristics are associated with the outcome. Summary Advanced statistical techniques may be insufficient for reducing confounding in observational studies. Evaluating the extent to which comparator selection may mitigate or induce systematic bias is a critical component of pharmacoepidemiologic studies.
Introduction
Randomized clinical trials (RCTs) are considered the gold standard to assess the effects of a treatment on a specific outcome because randomization and blinding remove many potential sources of bias. However, observational studies are often better positioned to evaluate the effectiveness and safety of drug exposures with respect to rare outcomes of interest (e.g., cancer) because they can include large and diverse study populations with extended follow-up. They are also critical to describing drug effects in real-world settings, as RCTs are often restricted to highly select populations with tightly controlled treatment monitoring. Large administrative databases with drug reimbursement and dispensing information are particularly useful, because they capture longitudinal exposure information for individuals across healthcare settings.
Robust study design reduces the potential for estimating biased treatment effects. When observational studies add the concept of a hypothetical intervention, usually resulting in a new user study design [1] , the choice of a comparator is one of the most critical components of study design. Three comparison choices are possible: the active comparator [2] , the inactive comparator [3••] , and the non-initiator comparator with the choice of the comparator depending on the research question and feasibility considerations. An active comparator is a specific drug or class of drugs with a similar indication and This article is part of the Topical Collection on Pharmacoepidemiology formulation as the treatment of interest. The choice of an active comparator depends upon the question of interest and whether class-level or drug-specific effects are known or hypothesized [4, 5] . An inactive comparator is a drug or class of drugs not indicated or used in the same way as the treatment of interest. Yet, an inactive comparator can help to "synchronize" cohorts on a variety of factors, including healthcare utilization and the start of study follow-up. The simplest comparator, in name but often not in implementation, is the non-initiator comparator. In this scenario, the comparator group is comprised of individuals not initiating a particular treatment. Non-initiator comparisons are often employed in the setting where an inactive or active comparator does not exist.
Several biases can arise in observational studies of drug effects, including: (1) time-related biases (e.g., immortal time bias, time-window bias, immeasurable time bias) [6] [7] [8] [9] , (2) confounding by frailty, (3) confounding by indication or derivations thereof, and (4) outcome detection bias. The potential for these biases depends, in large part, on the comparator selected. In the following sections, we will provide an overview of each of these biases and discuss how comparator selection (i.e., active comparator, inactive comparator, or non-initiator comparator) influences the likelihood of these biases. To contextualize these design decisions, we draw upon several contemporary examples from the pharmacoepidemiology literature to highlight considerations for comparator selection (summarized in Table 1 ) and close with a case study that walks through a structured decision-making process for selecting a comparator in a pharmacoepidemiologic study.
Overview of biases relevant to comparator selection
Several factors can influence treatment choice and may also be related to the outcome of interest, and thus confound observed estimates of treatment effects. In the simplest case when the comparison is no treatment (i.e., a non-initiator comparator), time-related biases such as immortal time bias can result from requiring no use of the drug of interest after cohort entry [6, 7] . This bias occurs because a natural synchronization between treatment initiation and non-initiation does not exist. Because time-related biases have been extensively described in the pharmacoepidemiologic literature [6-10], we will not provide further examples in this review.
Confounding by frailty [11••] occurs when certain therapies are differentially withheld from individuals in poor health, because there may be little to no benefit. This bias can lead to exaggerated beneficial treatment effects [12] . When the reason (or indication) for the treatment is also a risk factor for the outcome, confounding by indication [13] [14] [15] can occur. A variation of confounding by indication is confounding by disease severity. This occurs when disease severity is associated with the outcome, and also influences treatment choice. This type of bias can make a treatment appear more harmful than it is. A derivative of confounding by indication occurs when behaviors or characteristics associated with the primary indication for treatment are also risk factors for the outcome. Studies examining the effect of psychiatric medications may be particularly prone to this type of confounding because individuals with certain conditions, particularly if untreated, may be more likely to engage in unhealthy behaviors compared to the general population [16] [17] [18] [19] [20] [21] .
Outcome detection bias occurs when there is differential outcome ascertainment by treatment group [22, 23] . This bias can occur if overall health status or health seeking behavior influences if and when a person is diagnosed with the outcome. Although outcome detection bias is possible for many outcomes, cancers for which screening exists (e.g., prostate, colorectal, breast) may be particularly prone to detection bias. The likelihood of being diagnosed with cancer is influence by: (1) being healthy enough to be screened (diagnostic or routine), (2) adhering to screening guidelines, and (3) being engaged with the medical system. The same set of factors can also influence whether or not the same person will visit a physician and initiate certain types of medications. This form of bias can move in both directions. For example, statins may appear to increase cancer risk [24] , whereas Alzheimer's medications may be appear to reduce cancer risk.
Active comparators
Although active comparator studies have less potential for confounding than other studies (i.e., inactive and noninitiator comparators) because they restrict comparisons to patients initiating medications with similar indications, they can still suffer from confounding by disease severity and frailty.
Glargine and cancer risk
Because of concerns that the long-acting insulin analog glargine could increase the risk of cancer, Stürmer et al. [25] conducted a new user, active comparator study examining the association between insulin glargine versus human NPH insulin initiation and cancer. This study was performed within the Medical Outcomes Research for effectiveness and Economics registry between January 2003 and December 2010.
Body mass index (BMI) is associated with cancer risk and with diabetes but was un-measurable in the study dataset. BMI could therefore have been an important confounder. To address this issue, the authors examined the association between BMI and treatment choice in two external datasets and found that after controlling for other covariates, there was no association (adjusted odds ratio (aOR) 1.00, 95%CI 0.98, 1.02; 0.99 0.96-1.03). The authors concluded that there was no short-term association between glargine use and cancer incidence overall (aHR 1.11, 0.95-1.32), or breast, prostate or The inactive comparator was SSRI users. This medication class is used for long-term treatment of chronic conditions. It takes several weeks to notice symptom abatement. There is little potential for abuse. Benzodiazepines are frequently given in an as needed way and they work for the acute management of certain conditions. They have abuse potential. Habitual benzodiazepine users may be predisposed to higher mortality compared with SSRI users.
The authors used high dimensional propensity score models with many variables. They stratified into clinically meaningful age groups. They performed a sensitivity analysis with a comparator with overlapping indications. (1) with little known association with the outcome (2) that must be engaged with the healthcare system (3) that regularly takes a medication given for the long-term management of chronic disease, and that is commonly prescribed by a primary care physician (5) with a large number of anticipated initiators.
The authors had a strong understanding of the pathogenesis of CRC and used a wide set of clinically important covariates (including screening/diagnostic events) associated with CRC in the propensity score model. It was colon cancer incidence. When important potential confounders are unavailable in an observational study, it may be possible to investigate the potential for residual bias based on an external validation dataset.
Nicotine replacement therapy and cardiovascular disease
A study by Dollerup et al. [26] examined the association between nicotine replacement therapy (NRT) and cardiovascular disease in comparison to individuals receiving smoking cessation counseling (SCC) alone. Although the authors reported no association with cardiovascular disease after 4 weeks of treatment, the time to ischemic heart disease (aHR 1. [27] . Comparison with these medications may have reduced confounding by smoking severity, although this design is contingent on accurate identification of the smoking cessation indication.
Postoperative chemotherapy in older adults with rectal cancer
A study by Lund et al. [28] examined the association between postoperative chemotherapy and rectal cancer survival following preoperative chemoradiation or raditation among older patients. Using the cancer registry data linked with Medicare claims, the authors examined mortality differences between individuals who had received postoperative 5-fluorouracil (5-FU) or capecitabine, 5-FU/capecitabine plus oxaliplatin, or no chemotherapy. Compared to patients not receiving postoperative chemotherapy, postoperative 5-FU/capecitabine alone was associated with reduced mortality (aHR 0.46, 95%CI: 0.30-0.72) among patients aged 66-74. There was no observed effect among individuals older than 74 years. Although the authors controlled for measured confounding using propensity score weighting incorporating a wide array of clinical variables, they speculated that their study overestimated the benefits of post-operative chemotherapy. Even though this study was restricted to individuals healthy enough to initiate preoperative therapy and surgery, it is possible that individuals receiving postoperative chemotherapy were more robust than individuals not receiving chemotherapy. It may be impossible to fully control this bias, as has been shown previously in influenza studies [29••, 30, 31] . 
Inactive comparators
An alternative to non-users when the goal is to obtain a causal contrast [3••] between treatment and no treatment is a comparator for which there is no known association with the outcome. The use of an inactive treatment comparator helps reduce time-related biases by synchronizing the start of followup at medication initiation. However, identifying an appropriate comparator is challenging, because it has its own indications, and could be associated with the outcome. This approach has been previously referred to as an active comparator [32] [33] [34] [35] , a negative exposure control [36] , and an inactive comparator
There are a few key considerations when identifying an inactive comparator. First, the association between the inactive comparator and the outcome should be well-described. In practice it can be difficult to identify a treatment with a known association with the outcome, because it requires a treatment for which there is sufficient evidence. If the desired contrast is between use and non-use, then the inactive comparator should have evidence of no association with the outcome. Note that it is important to understand the association between an active comparator and an outcome to make proper inferences. For example, in a study evaluating the association between a new anti-hypertensive drug and angioedema with an active comparator of angiotensinconverting enzyme inhibitors (ACEIs). Any inferences would have to account for the well-known association between ACEIs and angioedema risk [37] or identify a different comparator with no known association with angioedema.
The inactive treatment should also be used in a similar way to the active treatment. For example, if the active treatment is indicated for the long-term management of a chronic disease, the inactive comparator should be used similarly and not used only for the treatment of acute symptoms. There should be a sufficient number of anticipated users to allow precise estimation, with another consideration being the projected number of concomitant users, who would be ineligible for analysis. Finally, the risk factors for the outcome should be wellknown, with the most important being directly measurable in the data.
Benzodiazepines and mortality
A recent study examined the association between benzodiazepines and mortality [35] , with the primary comparison group consisting of randomly selected high-dimensional propensity score matched non-users who had visited a physician within 14 days of the matched benzodiazepine initiator. To minimize access to healthcare differences, they required that both nonusers and benzodiazepine users filled at least one nonbenzodiazepine prescription in the 0-90 and 91-180 days prior to the index date. They reported no association between benzodiazepine initiation and non-initiation. In a sensitivity analysis, they compared benzodiazepine initiators to selective serotonin reuptake inhibitors (SSRI) initiators, because with the exception of a small increased risk of suicide among adolescents and young adults [38] , SSRIs are not associated with increased mortality. This analysis represents an inactive comparison, because the medications lack similarity in indication. Additionally, how these medications are taken varies substantially. SSRIs are used for the long-term management of various conditions including depression, anxiety, sleep disorders, and chronic pain [39, 40] . They are taken daily over months and years, and it can take few weeks to notice symptom reduction. In contrast, benzodiazepines are used for the acute treatment of anxiety, panic, and sleep disorders. They are controlled substances with the potential for abuse, with prescribers potentially being more hesitant to prescribe these medications for long periods of time. Benzodiazepines are commonly prescribed on an "as-needed" basis, whereas SSRIs are taken daily. These differences in the two underlying populations may explain the small, albeit increased risk of death associated with the benzodiazepine initiators (aHR 1.09, 95%CI 1.03-1.16). Because of the risk for abuse, it could be reasoned that individuals who take benzodiazepines regularly instead of SSRIs may have a higher propensity for substance abuse and other related but unmeasurable factors that differentially increase mortality.
Non-user comparators
When there is no clear alternative to the treatment of interest, many studies employ non-initiator comparisons, whereby individuals initiating a treatment of interest are compared to individuals not initiating that treatment. Although, noninitiator comparisons are particularly prone to immortal time bias, there are strategies to reduce this bias [41] . There are also more advanced adjustment techniques such as propensity scores and a special case, high-dimensional propensity scores, [42] to reduce the risk of measured confounding (see example 4 above). Unmeasured confounding, especially with respect to drug indication and frailty remain since these are difficult to measure.
Influenza vaccine and mortality
Although numerous studies [43] [44] [45] [46] [47] [48] have documented the strong inverse association between receiving the flu vaccine and mortality, there is sound evidence that a substantial proportion of these associations are due to the underlying differences in the populations that received or did not receive the vaccine. Individuals who were close to death and were thus not expected to survive the flu season, may have been less likely to get vaccinated. In contrast, individuals who received the vaccine were perceived as healthy enough to benefit from the vaccine. In a classic example, Jackson et al. [29••] addressed this hypothesis by examining the association between influenza vaccination versus no vaccination and death prior to the influenza season, a negative control outcome that should not be affected by influenza vaccination. The authors found that vaccine receipt was associated with a substantial reduction in mortality (risk ratio (RR) = 0.39, 0.33-0.47). Moreover, adjustment for important diagnosis codes did not materially alter the association, underscoring the challenge of controlling for frailty by adjustment for measured variables contained within administrative data. A contemporary study [31] attempted to reduce confounding by frailty in similar setting, by adjustment for markers of independent living, as a proxy for health status. The association with mortality was attenuated compared with the previous study (HR 0.68, 0.67-0.70), but the authors concluded that substantial confounding remained despite more rigorous health status measurement.
Statins, antibiotics, and breast cancer outcomes
A study by Wirtz et al. [49•] aimed to understand why previous studies within the same parent study had reported increased risks of second breast cancers associated with antibiotic use [50, 51] , and decreased risk of recurrent breast cancer associated with statin use [52] . All studies compared medication users to non-users. In the follow-up study, they examined screening practices of the antibiotic or statin users. Adherent statin use was associated with more surveillance mammography (odds ratio (OR) 1.11, 95%CI 1.01-1.25) compared to non-users, whereas heavy antibiotic use was associated with less surveillance mammography (OR 0.90, 95%CI 0.82-0.99). Although adjustment for screening behaviors did not qualitatively impact inferences, this study highlights how screening practices can vary among initiators of various medication classes.
Lithium and pregnancy outcomes
Lithium is one of the primary treatments of bipolar disorder, a condition that affects~1-2.5% of the population [53] . Untreated, individuals with bipolar disorder may engage in dangerous behaviors (e.g., substance abuse) [18, 19, 53, 54] that could negatively impact fetal development. Untreated women may also be more likely to forgo early prenatal care. Concerns over the safety of lithium in early pregnancy [55, 56] prompted Patorno et al. [57] to examine the association between lithium use in the first trimester of pregnancy and the risk of fetal cardiac malformations. This important question is challenging because it is difficult to disentangle bipolarassociated behaviors and medications on fetal outcomes. A woman who was untreated at conception may have been engaging in behaviors that, on their own, could have negatively impacted fetal development.
In the primary analysis, the authors compared women who used lithium (without requiring a bipolar diagnosis) in the first trimester of their pregnancy with women who did not use lithium based on Medicaid data. The authors controlled for measured confounding using a matched propensity score approach containing a rich set of variables. The study reported an increased risk associated with lithium (adjusted hazard ratio (aHR) 1.65, 95%CI 1.02-2.68) in this population. It is however, possible that untreated bipolar women appearing in the nonuser group may have biased the relative association towards the null. Although the proportion of women with a bipolar diagnosis was relatively small in the non-user group, untreated women could have obscured the risk in the non-user group.
To address potential confounding by indication, the authors performed an analysis restricted to women with a bipolar diagnosis, where individuals using lithium were compared to individuals using lamotrigine, also indicated for bipolar disorder (i.e., an active comparator). Lamotrigine is not associated with the risk of cardiac malformations. Both the comparison to lamotrigine exposed women and the restriction to individuals with a bipolar diagnosis may have reduced confounding by unhealthy behaviors in bipolar women. Characteristics of lamotrigine and lithium exposed women were similar with respect to mental health diagnoses and other comorbidities before propensity score weighting. The association in this comparison was similar (aHR 2.25, 95%CI 1.17-4.34), albeit higher than the other comparison.
Case study: antidepressants and colorectal cancer
As a case study, we explored designing a study to evaluate the association between SSRI use and incident colorectal cancer (CRC). We were also interested in two other classes: serotonin norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs). Here, we will walk through the process of selecting a comparator and the considerations, such as important covariate availability that could influence study results (see Table 1 for summary).
Comparator choice considerations
An active comparator, if it exists, is generally ideal to minimize the risk of bias. As noted earlier, psychiatric drugs may be particularly prone to confounding because of behaviors associated with the indication. However, we could not identify a comparator with a similar indication without evidence of an association with CRC risk [58] [59] [60] [61] . We next considered other psychotropic drugs, but there was insufficient evidence to state with certainty that they were not associated with CRC risk. Additionally, some anti-psychotics are also differentially given to individuals with late stage dementia to improve behavior [62, 63] even without a history of psychosis. Those individuals are less likely to be screened and diagnosed with a cancer, which could lead to outcome detection bias.
Given that we could not identify an active comparator, we preferred to select a group of individuals initiating a medication taken daily for the management of a chronic disease. We sought to identify a comparator that was commonly prescribed by a primary care physician, because they also commonly prescribe SSRIs, except in the case of more severe mental illness. For these reasons, we ruled out selection of non-initiators. Practically, it is also more straightforward to the start follow-up at medication initiation.
We briefly considered selecting anti-glaucoma drugs as an inactive comparator, because it has been previously used in the published literature [32] [33] [34] 64] . We were, however, concerned that these drugs are generally prescribed by an ophthalmologist. This provider may not be aware of the patients' overall health issues, as a primary care physician would. These medications may not be given in for "long-term" use, in a prophylactic manner, but more for symptom abatement. We were also not convinced that there would be a sufficient number of initiators in the data. Statins were excluded because there is ongoing debate as to whether they are associated with cancer risk [65, 66] . There is a substantial body of evidence on anti-hypertensives (AHT), enough to state with some certainty that they do not dramatically alter CRC risk, and limited evidence that some may reduce risk [67] , with the exception of beta-blockers where evidence suggests a reduced cancer risk [68] . Additionally, primary care physicians generally treat hypertension.
Identifying risk factors in administrative data
We thus moved forward with a new user [69] study design with an AHT inactive comparator using a Medicare beneficiary population [70] . We a priori hypothesized that all three antidepressant (AD) classes had "late-acting" effects on CRC risk such that the medications were acting close to the adenoma-carcinoma transition. We therefore hypothesized that we could detect associations with only a few years of follow-up data. The natural history of CRC has been fairly well documented [71] [72] [73] [74] , with major risk factors generally identified [75] . We were thus aware of which risk factors were measurable. Age, male sex, history of inflammatory conditions, and black race are all strong risk factors for which we had information. Family history and genetics [75] are strong risk factors that were unmeasurable. We used diagnoses for all non-CRC prior to initiation as a proxy for upstream genetic predisposition to cancer generally. We had information or proxies for hormone replacement therapy, non-steroidal antiinflammatory use, diabetes, alcohol consumption, smoking and obesity, all of which modestly affect CRC risk [75] . We lacked information on diet, exercise, BMI, or aspirin (generally unavailable) use.
Potential for confounding by indication derivative
Limited evidence suggests that depressed individuals, for which antidepressants are indicated, may be less like to adhere to screening guidelines [76, 77] and would be less likely to be screened or visit a physician. In turn, they may be less likely to be diagnosed with CRC. This could lead to outcome detection bias if we did not have information on screening behaviors. Administrative data do however contain information on CRC screening and diagnostic events, because Medicare pays for these services [78] . We therefore would be able to control for recent screening behavior that may be influenced by depression status. Finally, if antidepressants improve depressive symptoms, then screening may not be a concern after a few months of follow-up.
Antidepressants and CRC results
We identified 530,304 SSRI, SNRI, TCA, or AHT initiators with a second prescription meeting age, enrollment, and CRCfree status criteria. Substantially more individuals exclusively initiated an AHT (n = 417,491) class than an AD (SSRI: n = 87,401 SNRIs: n = 12,211; TCAs: n = 13,201). The median days of continuous medication class use after the second prescription (overall = 332 days) varied across classes [AHT = 363; SSRI = 252; TCA = 172; SNRI = 238 days].
We observed 1,728 CRC events in 631,920 person years (PY), with incidence varying from 214 per 100,000 PY for TCA initiators to 281 cases per 100,000 PY for AHT initiators. SSRI initiators had a reduced rate of CRC compared with AHT initiators: (aHR 0.85 95%CI 0.71-1.00). TCA and SNRI initiators had lower adjusted CRC rates compared with AHT initiators [0.83, 0.52-1.31; 0.91, 0.59, 1.41], respectively. In sensitivity analyses, we observed a reduced rate (5-20%) of CRC among SSRI users compared with AHT initiators. These associations fell within the range of previously reported estimates [79] [80] [81] [82] [83] [84] .
Our comparator was not perfect. Limitations included a large reduction in sample size due to concomitant AD and AHT users, and differences in follow-up time. Because we lacked absolute proof that our AHT comparator was not associated with CRC, it may have been informative to perform sensitivity analyses with additional inactive comparators that we hypothesized had no association with the outcome. A similar strategy was used in a study of immune-related conditions and the risk of keratinocyte cancers [85] . However, the data we used contained information on key variables, proxies for other factors, and managed to perfectly balance these factors. We also compared drug classes that required somewhat regular physician interaction. As such, our analysis provides some evidence that SSRIs do not increase the risk of CRC compared to AHT in a Medicare population.
Conclusions
Comparator selection in observational pharmacoepidemiologic studies is infrequently straightforward. In general, systematic bias is always a threat because of the potential for unmeasured confounding. However, it is possible to carefully design and select a comparator that may reduce the potential for bias, weighing each of the considerations mentioned in Table 1 . It is critical to understand (1) the population in whom the treatment is given, to (2) how patient characteristics are associated with the outcome, and (3) the natural history and risk factors for the outcome. Advanced statistical techniques may be insufficient for reducing confounding in observational studies. Thus, complementary strategies such as the use of active comparators or addressing the extent to which bias may impact estimated treatment effects (e.g., via validation studies and multiple bias modeling) represent promising directions for future studies.
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